🇺🇸 FDA
Pipeline program

Efgartigimod PH20 SC

ARGX-113-2306

Phase 3 mab active

Quick answer

Efgartigimod PH20 SC for Primary Sjogrens Disease is a Phase 3 program (mab) at argenx with 1 ClinicalTrials.gov record(s).

Program details

Company
argenx
Indication
Primary Sjogrens Disease
Phase
Phase 3
Modality
mab
Status
active

Clinical trials